在危重症患者中使用基于药代动力学/药效学的剂量计算器评估头孢吡肟、美罗培南和哌拉西林他唑巴坦的药效学目标达成情况。
Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients.
机构信息
University of Maryland School of Pharmacy, Baltimore, Maryland, USA
Center for Anti-Infective Research, Hartford Hospital, Hartford, Connecticut, USA.
出版信息
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.01008-18. Print 2018 Sep.
Abstract
This was a prospective study to determine if pharmacokinetic/pharmacodynamic (PK/PD)-based antibiotic dosing software aids in achieving concentration targets in critically ill patients receiving cefepime ( = 10), meropenem ( = 20), or piperacillin-tazobactam ( = 19). Antibiotic calculator doses targeting a >90% probability of target attainment (PTA) differed from package insert doses for 22.4% (11/49) of patients. Target attainment was achieved for 98% of patients (48/49). A PK/PD-based antibiotic dosing calculator provides beta-lactam doses with a high PTA in critically ill patients.
摘要
这是一项前瞻性研究，旨在确定基于药代动力学/药效学（PK/PD）的抗生素剂量计算软件是否有助于达到接受头孢吡肟（= 10）、美罗培南（= 20）或哌拉西林他唑巴坦（= 19）治疗的危重症患者的浓度目标。抗生素计算器剂量的目标是达到 >90%的目标命中率（PTA），与 22.4%（11/49）的患者的用药说明书剂量不同。98%的患者（48/49）达到了目标。基于 PK/PD 的抗生素剂量计算为危重症患者提供了具有高 PTA 的β-内酰胺剂量。
相似文献
1
Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients.
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.01008-18. Print 2018 Sep.
2
Time Above All Else: Pharmacodynamic Analysis of β-Lactams in Critically Ill Patients.
J Clin Pharmacol. 2022 Apr;62(4):479-485. doi: 10.1002/jcph.1977. Epub 2021 Nov 12.
3
OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
Farm Hosp. 2019 Sep 1;43(5):151-157. doi: 10.7399/fh.11170.
4
Continuous Infusion of Piperacillin/Tazobactam and Meropenem in ICU Patients Without Renal Dysfunction: Are Patients at Risk of Underexposure?
Eur J Drug Metab Pharmacokinet. 2021 Jul;46(4):527-538. doi: 10.1007/s13318-021-00694-0. Epub 2021 Jun 15.
5
Emergence of antimicrobial resistance to piperacillin/tazobactam or meropenem in the ICU: Intermittent versus continuous infusion. A retrospective cohort study.
J Crit Care. 2018 Oct;47:164-168. doi: 10.1016/j.jcrc.2018.07.003. Epub 2018 Jul 4.
6
Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
Crit Care Med. 2005 Oct;33(10):2222-7. doi: 10.1097/01.ccm.0000181528.88571.9b.
7
Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
Crit Care. 2013 May 3;17(3):R84. doi: 10.1186/cc12705.
8
Beta-lactam antibiotic concentrations in critically ill patients with standard and adjusted dosages: A prospective observational study.
Acta Anaesthesiol Scand. 2024 Apr;68(4):530-537. doi: 10.1111/aas.14382. Epub 2024 Feb 26.
9
A pilot study on pharmacokinetic/pharmacodynamic target attainment in critically ill patients receiving piperacillin/tazobactam.
Anaesthesiol Intensive Ther. 2016;48(1):23-8. doi: 10.5603/AIT.a2015.0082. Epub 2015 Nov 20.
10
Optimal antipseudomonal ꞵ-lactam drug dosing recommendations in critically-ill Asian patients receiving CRRT.
J Crit Care. 2022 Dec;72:154172. doi: 10.1016/j.jcrc.2022.154172. Epub 2022 Oct 18.
引用本文的文献
1
Dose Individualisation of Antimicrobials from a Pharmacometric Standpoint: The Current Landscape.
Drugs. 2024 Oct;84(10):1167-1178. doi: 10.1007/s40265-024-02084-7. Epub 2024 Sep 6.
2
Unraveling the impact of therapeutic drug monitoring via machine learning for patients with sepsis.
Cell Rep Med. 2024 Aug 20;5(8):101681. doi: 10.1016/j.xcrm.2024.101681. Epub 2024 Aug 9.
3
Factors Influencing Integration and Usability of Model-Informed Precision Dosing Software in the Intensive Care Unit.
Appl Clin Inform. 2024 Mar;15(2):388-396. doi: 10.1055/s-0044-1786978. Epub 2024 May 16.
4
Antimicrobial Multidrug Resistance: Clinical Implications for Infection Management in Critically Ill Patients.
Microorganisms. 2023 Oct 16;11(10):2575. doi: 10.3390/microorganisms11102575.
5
The Significance of Bayesian Pharmacokinetics in Dosing for Critically Ill Patients: A Primer for Clinicians Using Vancomycin as an Example.
Antibiotics (Basel). 2023 Sep 13;12(9):1441. doi: 10.3390/antibiotics12091441.
6
International survey of antibiotic dosing and monitoring in adult intensive care units.
Crit Care. 2023 Jun 19;27(1):241. doi: 10.1186/s13054-023-04527-1.
7
The Current Status and Future Perspectives of Beta-Lactam Therapeutic Drug Monitoring in Critically Ill Patients.
Antibiotics (Basel). 2023 Mar 30;12(4):681. doi: 10.3390/antibiotics12040681.
8
Can precision antibiotic prescribing help prevent the spread of carbapenem-resistant organisms in the hospital setting?
JAC Antimicrob Resist. 2023 Mar 29;5(2):dlad036. doi: 10.1093/jacamr/dlad036. eCollection 2023 Apr.
9
Impact of renal replacement therapy strategy on beta-lactam plasma concentrations: the BETAKIKI study-an ancillary study of a randomized controlled trial.
Ann Intensive Care. 2023 Feb 25;13(1):11. doi: 10.1186/s13613-023-01105-0.
10
Antimicrobial Exposure in Critically Ill Patients with Sepsis-Associated Multi-Organ Dysfunction Requiring Extracorporeal Organ Support: A Narrative Review.
Microorganisms. 2023 Feb 13;11(2):473. doi: 10.3390/microorganisms11020473.
本文引用的文献
1
MIC-based dose adjustment: facts and fables.
J Antimicrob Chemother. 2018 Mar 1;73(3):564-568. doi: 10.1093/jac/dkx427.
2
The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.
Intensive Care Med. 2017 Jul;43(7):1021-1032. doi: 10.1007/s00134-017-4780-6. Epub 2017 Apr 13.
3
Comparative Evaluation of the Predictive Performances of Three Different Structural Population Pharmacokinetic Models To Predict Future Voriconazole Concentrations.
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6806-6812. doi: 10.1128/AAC.00970-16. Print 2016 Nov.
4
The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs.
J Antimicrob Chemother. 2015 Sep;70(9):2671-7. doi: 10.1093/jac/dkv165. Epub 2015 Jul 13.
5
Comparison of the accuracy and precision of pharmacokinetic equations to predict free meropenem concentrations in critically ill patients.
Antimicrob Agents Chemother. 2015 Mar;59(3):1411-7. doi: 10.1128/AAC.04001-14. Epub 2014 Dec 15.
6
Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.
Lancet Infect Dis. 2014 Jun;14(6):498-509. doi: 10.1016/S1473-3099(14)70036-2. Epub 2014 Apr 24.
7
DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?
Clin Infect Dis. 2014 Apr;58(8):1072-83. doi: 10.1093/cid/ciu027. Epub 2014 Jan 14.
8
Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?
Antimicrob Agents Chemother. 2013 Dec;57(12):6165-70. doi: 10.1128/AAC.00951-13. Epub 2013 Sep 30.
9
Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.
Ann Intensive Care. 2012 Jul 28;2(1):35. doi: 10.1186/2110-5820-2-35.
10
Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.
Crit Care. 2011;15(5):R206. doi: 10.1186/cc10441. Epub 2011 Sep 13.
Zotero 插件